Dec. 5 at 4:01 PM
$ONCY Of note: Roche, Royalty Pharma, and Revolution Medicines (RVMD) are linked through a 2025 strategic funding arrangement for RVMD's oncology pipeline, where Roche provides collaborative development support and Royalty Pharma supplies non-dilutive financing via royalties and debt.
Roche maintains a multi-year strategic collaboration with RVMD focused on advancing RAS-targeted precision oncology drugs, including development funding and milestones potentially worth up to 2 billion total to RVMD, without equity ownership or direct royalties for Roche.
Royalty Pharma committed up to 2 billion to RVMD in June 2025, comprising
$1.25 billion in synthetic royalties on future RAS inhibitor sales (e.g., daraxonrasib) and
$750 million in secured debt, enabling RVMD to retain full development and commercialization control.
No direct tie exists between Roche & Royalty Pharma specific to RVMD; their interactions are indirect through past royalty purchases on Roche-partnered assets.
